contusugene ladenovec

AXP000142.1 · Viral vector gene therapy

Platform
adenovirus (Ad5, E1-deleted, CMV promoter-driven TP53)
Targets
TP53
Originator
Introgen Therapeutics
Sponsor
Introgen Therapeutics

Names

NameTypeSource
contusugene ladenovecpreferred name, INNcurator, ncit
Advexinbrandncit
INGN 201codencit
Ad-p53 ambiguoussynonymncit
Ad5CMV p53 Gene ambiguoussynonymncit
RPR/INGN-201former codencit

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
E1-deleted (replication-defective); CMV promoter-driven wild-type TP53
Transgenes
TP53
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C2471
FDA UNII
YPN57899MY

Approvals

No regulatory approval recorded.

Clinical trials (9)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT01302821C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast CancerWithdrawn2013-012014-120Breast Cancer
NCT00410865Wild Type p53 Adenovirus for Oral PremalignanciesTerminatedPhase 12003-062008-034Mouth Cancer
NCT00064103Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or PharynxCompletedPhase 1/22003-062007-0851Lip and Oral Cavity Cancer; Oropharyngeal Cancer; Stage 0 Lip and Oral Cavity Cancer; Stage 0 Oropharyngeal Cancer; Tongue Cancer
NCT00017173S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or ThroatTerminatedPhase 22003-022007-0513Head and Neck Cancer
NCT00044993Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast CancerCompletedPhase 22002-02Breast Cancer
NCT00003167Gene Therapy in Treating Patients With Advanced Bladder CancerCompletedPhase 11998-052002-1224Recurrent Bladder Cancer; Stage I Bladder Cancer; Stage II Bladder Cancer; Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder
NCT00286247Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast CancerCompletedPhase 260Locally Advanced Breast Cancer (LABC)
NCT00041626Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy AloneUnknownPhase 3Carcinoma, Squamous Cell
NCT00041613Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving MethotrexateUnknownPhase 3Carcinoma, Squamous Cell
Unconfirmed matches (12)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT07150416Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical StudyNot yet recruitingPhase 22025-10-012026-12-0138Lung Neoplasms; Multiple Pulmonary Ground-Glass Nodules; Precancerous Conditionsname in intervention: Ad-p53
NCT02842125Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell CancerTerminatedPhase 1/22018-11-202020-05-084Metastatic Solid Tumor Cancer; Recurrent Head and Neck Cancerintervention named: Ad-p53
NCT03544723Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.UnknownPhase 22018-10-012022-06-3040Lymphoma; Solid Tumorintervention named: Ad-p53
NCT01042535Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast CancerCompletedPhase 1/22009-12-282014-12-0144Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specificname in intervention: Ad-p53
NCT00004225Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung CancerCompletedPhase 12000-01Lung Cancerintervention named: Ad5CMV p53 Gene
NCT00004041Gene Therapy in Treating Patients With Recurrent Malignant GliomasCompletedPhase 11999-02-252002-07-22Brain and Central Nervous System Tumorsintervention named: Ad5CMV p53 Gene
NCT00004038Gene Therapy Plus Chemotherapy in Treating Patients With Breast CancerCompletedPhase 11999-012001-0520Breast Cancerintervention named: Ad5CMV p53 Gene
NCT00003649Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically RemovedCompletedPhase 11998-11-17Lung Cancerintervention named: Ad5CMV p53 Gene
NCT00003588Gene Therapy in Treating Patients With Ovarian CancerCompletedPhase 11998-092002-0330Ovarian Cancerintervention named: Ad5CMV p53 Gene
NCT00003450Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal CancerCompletedPhase 11998-091999-01Ovarian Cancer; Peritoneal Cavity Cancerintervention named: Ad5CMV p53 Gene
NCT00003147Gene Therapy in Treating Patients With Cancer of The LiverTerminatedPhase 11998-022003-0630Liver Cancerintervention named: Ad5CMV p53 Gene
NCT00003257Gene Therapy in Treating Patients With Recurrent Head and Neck CancerUnknownPhase 21998-0139Head and Neck Cancerintervention named: Ad5CMV p53 Gene

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 19770418A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group.Archives of otolaryngology--head & neck surgery2009cited by trial NCT00017173
PMID 19086841Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.Future oncology (London, England)2008name in title: Advexin
PMID 17483435p53 therapy in a patient with Li-Fraumeni syndrome.Molecular cancer therapeutics2007name in abstract: Advexin
PMID 16648505Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2006name in abstract: INGN 201
PMID 16734736Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.Cancer science2006name in abstract: INGN 201
PMID 15297186A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.Gynecologic oncology2004name in title: INGN 201
PMID 15553716[A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy].Gan to kagaku ryoho. Cancer & chemotherapy2004name in abstract: Advexin
PMID 12538456Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.Clinical cancer research : an official journal of the American Association for Cancer Research2003name in title: INGN 201
PMID 12805322Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2003name in abstract: INGN 201
PMID 12839017Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2003name in abstract: INGN 201
PMID 14599679Development and validation of a real-time PCR assay for the detection and quantitation of p53 recombinant adenovirus in clinical samples from patients treated with Ad5CMV-p53 (INGN 201).Journal of virological methods2003name in title: INGN 201
Unconfirmed matches (3)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 30591959Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.Cancer immunology, immunotherapy : CII2019name in title: Ad-p53
PMID 19958629[Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer].Ai zheng = Aizheng = Chinese journal of cancer2009name in title: Ad-p53
PMID 10811470Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).Cancer gene therapy2000name in title: Ad-p53

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 35756634Role of Adenoviruses in Cancer Therapy.Frontiers in oncology2022name in abstract: Advexin
PMID 31933185Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.Pharmaceutical medicine2019name in abstract: Advexin
PMID 26052534Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera.Molecular therapy. Methods & clinical development2015name in abstract: contusugene ladenovec
PMID 25364261Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.OncoTargets and therapy2014name in abstract: Advexin
PMID 24107178Advances in adenovirus-mediated p53 cancer gene therapy.Expert opinion on biological therapy2013name in abstract: Advexin
PMID 20222046Head and neck cancer: response to p53-based therapeutics.Head & neck2011name in abstract: Advexin
PMID 20501801Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer.Molecular cancer therapeutics2010name in abstract: Advexin
PMID 19169960A review of contusugene ladenovec (Advexin) p53 therapy.Current opinion in molecular therapeutics2009name in title: contusugene ladenovec
PMID 20021420Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications.Current molecular pharmacology2008name in abstract: Advexin
PMID 17472413INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.Drugs in R&D2007name in title: RPR/INGN-201
PMID 16856803INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.Expert opinion on biological therapy2006name in title: INGN 201
PMID 15102659Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2004name in abstract: INGN 201
PMID 12749760INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2003name in title: RPR/INGN-201
PMID 14617796Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity.Molecular cancer therapeutics2003name in abstract: INGN 201
PMID 11339893Tumor suppression and therapy sensitization of localized and metastatic breast cancer by adenovirus p53.Human gene therapy2001name in abstract: RPR/INGN-201
PMID 11706402Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies.Seminars in oncology2001name in title: INGN 201
PMID 11892946INGN-201. Introgen Therapeutics.Current opinion in investigational drugs (London, England : 2000)2001name in title: INGN 201
PMID 11121656Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.International journal of radiation oncology, biology, physics2000name in abstract: RPR/INGN-201
PMID 11122810Local delivery for gene therapy.Current oncology reports1999name in abstract: RPR/INGN-201
Unconfirmed matches (22)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 29338444The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.Human gene therapy2018name in title: Ad-p53
PMID 25501339Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.Oncology reports2015name in title: Ad-p53
PMID 25876901[Effects of Ad-p53 plus fulvestrant on induced apoptosis in MCF-7 breast cancer cells].Zhonghua yi xue za zhi2015name in title: Ad-p53
PMID 25623760[Effect of recombinant human p53 adenovirus (Ad-p53) combined with EGFR inhibitor gefitinib on the sensitivity of breast cancer MDA-MB-468 cells].Zhonghua zhong liu za zhi [Chinese journal of oncology]2014name in title: Ad-p53
PMID 20015717Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model.American journal of otolaryngology2010name in title: Ad-p53
PMID 20420527INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.Expert opinion on biological therapy2010name in title: Ad-p53
PMID 18443131Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis.Neuro-oncology2008name in title: Ad-p53
PMID 18790766AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer.Molecular cancer therapeutics2008name in title: Ad-p53
PMID 16886630Ad-fRNK and Ad-p53 cooperate to augment drug-induced death of a transformed cell line.Anticancer research2006name in title: Ad-p53
PMID 16149900Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.Human gene therapy2005name in title: Ad-p53
PMID 14719118Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.International journal of oncology2004name in title: Ad-p53
PMID 15510008Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer.The Laryngoscope2004name in title: Ad-p53
PMID 12521996Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells.Blood2003name in title: Ad-p53
PMID 14682374Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses.Journal of neuro-oncology2003name in title: Ad-p53
PMID 12082456Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.Cancer gene therapy2002name in title: Ad-p53
PMID 12487055Clinical update of Ad-p53 gene therapy for lung cancer.Surgical oncology clinics of North America2002name in title: Ad-p53
PMID 11296482Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis.Neuro-oncology2001name in title: Ad-p53
PMID 10733544Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment.Hepatology (Baltimore, Md.)2000name in title: Ad-p53
PMID 10854146Ad5CMVp53 gene therapy for locally advanced prostate cancer--where do we stand?World journal of urology2000name in title: Ad5CMV p53 Gene
PMID 11798837[Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82].Zhonghua yi xue za zhi2000name in title: Ad-p53
PMID 10516606Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacy.Cytometry1999name in title: Ad-p53
PMID 12496806Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results.Prostate cancer and prostatic diseases1999name in title: Ad-p53

NIH grants

No confirmed grants yet.

Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

ProjectTitleOrganisationPIYearsLinked by
R21DE014878Enhancement of Ad-p53 Therapy with Intratumoral TaxaneWAYNE STATE UNIVERSITYYOO, GEORGE H2003–2004name in title: Ad-p53

Notes

Advexin; reached phase 3 in head and neck squamous cell carcinoma. FDA told Introgen in 2008 that the BLA was not sufficiently complete to file; the company restructured and the programme stopped. Ad5CMV-p53 is the construct name.

How to cite

contusugene ladenovec (AXP000142.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000142.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.